NHS Framework for the NHS London Region, Branded Medicines - Tranche A
Estimated value
£301.1m
Awarded value
£191.1m
Suppliers
1
Lots
1
Published
15 Sept 2020
Description
NHS Framework for the NHS London Region, Branded Medicines - Tranche A, Annual Tranche - Cytokine Modulators and other products, and Dolutegravir / Lamivudine Offer reference number: CM/PHR/16/5516 CM/PHR/16/5516/01 - London Tranche A - 1 September 2020 to 31 August 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/16/5516/02 - London Annual Tranche - Cytokine Modulators and other products - 1 September 2020 to 31 August 2021 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/16/5516/03 - NHS Framework agreement for the supply of Dolutegravir / Lamivudine - North of England - 1 September 2020 - 28 February 2021, South of England - 1 September 2020 - 31 August 2021, Midlands & East - 1 September 2020 - 28 February 2022, all with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
Scope
- Reference
- tender_232387/865787
- Total value
- £301,101,314 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2020 to 30 Aug 2022
- CPV classifications
- 33600000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 15 Apr 2020, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£191.1m
Award date
16 Jun 2020
Contract start
31 Aug 2020
Contract end
30 Aug 2022